$heff's $tation of $tocks & $olid DD

[$heff]

PATH..$4.55 looks attractive if the market was healthy & there was a potential move higher into their PDUFA. Because they are a "first-timer" with the FDA, it is important to remove your risk associated with the stock. The main issue I have is that it is a bulky device that a patient has to wear. It also seems that the drug arm & the device arm of the FDA have to decide on this moving forward. It may require more clinical trials IMO. They are using a 505(B)route through the FDA but it is hard to know what or if the FDA is looking for. You have these questions answered with a CRL or an Advisory Panel. First time companies have gotten approved like CLDA, but they are too risky for my blood. Even companies that have had CRL's still often don't address the concerns of the FDA like TSPT recently. Just my thoughts. Enough risk in the market than to introduce more of it to your portfolio.